OCT 11, 2017 10:30 AM PDT

Characterization and application of the triple immunodeficient R2G2 (Rag2/Il2rg double knockout) mouse model

SPONSORED BY: Envigo
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Chief Scientific Officer - Biologics, Envigo
    Biography
      Lee was recruited by Huntingdon Life Sciences at the end of 2004 to take a leading role in working with customers developing biopharmaceutical products.

      Lee brought to the role hands-on experience of biopharmaceutical drug development gained in companies such as; Cantab Pharmaceuticals, Xenova and CellFactors. During his time in the biotechnology industry, he was involved in developing therapies including: vaccines, recombinant proteins; monoclonal antibodies; immunomodulatory molecules; viral and non-viral gene delivery systems; and cell-based therapies.

      He has a well-rounded knowledge of the regulatory environment for biologics and particular expertise in the analysis of protein and viral products.

      At Envigo, Lee is Chief Scientific Officer - Biologics. He is also a serving committee member on the Monoclonal Antibody Expert Working Group of the National Centre for the 3Rs, The BIA Manufacturing Advisory Committee, the RSC / RPS Joint Pharmaceutical Analysis Group the ABPI Nonclinical and Biological Discovery Expert Network (NaBDEN) committee.

    Abstract:

    The “R2G2” (B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd) knockout mouse is the latest advancement to provide an alternative option in the highly immunodeficient mouse model category for oncology, immunology and other biomedical research communities. This model was generated by backcrossing an IL2rg (common gamma) knockout model to a RAG2 (recombinase activating gene) knockout model. The resulting mouse lacks various cytokines including IL-2, IL-4, IL-7, IL-9 and IL-15. In addition, this model lacks B cells, T cells, NK cells and has a deficiency in lymphocyte development. The R2G2 mouse model is not only ultra immunodeficient, but provides a model that is less leaky and more tolerant to gamma radiation than traditional SCID models. Herein we describe the development and characterization of the R2G2 mouse model, which includes breeding history, growth curve, complete blood count and serum chemistry, flow cytometry, tumor growth and radiosensitivity.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 24, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    MAY 29, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 29, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    Loading Comments...